Patents by Inventor Peter Joseph Cassidy

Peter Joseph Cassidy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9340517
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: May 17, 2016
    Assignee: Mimetica PTY LTD
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Publication number: 20140128380
    Abstract: The present invention provides compounds of Formula (I) that are useful for binding and/or modulating the biological activity of the melanocortin-1 receptor (MC1R). Compounds of this invention can be used to treat diseases and/or conditions in which modulation of MC1R is beneficial. Such diseases and/or conditions include, but are not limited to, hyperpigmentation (including melasma), hypopigmentation (including vitiligo), melanoma, basal cell carcinoma, squamous cell carcinoma, erythropoietic protoporphyria, polymorphous light eruption, solar urticaria, photosensitivity, sunburn, inflammatory diseases, aberrant fibroblast activity and pain.
    Type: Application
    Filed: January 13, 2014
    Publication date: May 8, 2014
    Applicant: Mimetica Pty Ltd
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Patent number: 8440653
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: May 14, 2013
    Assignee: Mimetica Pty Ltd
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Patent number: 8377925
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: February 19, 2013
    Assignee: Mimetica Pty Ltd
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Patent number: 8343958
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: January 1, 2013
    Assignee: Mimetica Pty Ltd
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Publication number: 20120141392
    Abstract: The present invention provides compounds of Formula (I) that are useful for binding and/or modulating the biological activity of the melanocortin-1 receptor (MC1R). Compounds of this invention can be used to treat diseases and/or conditions in which modulation of MC1R is beneficial. Such diseases and/or conditions include, but are not limited to, hyperpigmentation (including melasma), hypopigmentation (including vitiligo), melanoma, basal cell carcinoma, squamous cell carcinoma, erythropoietic protoporphyria, polymorphous light eruption, solar urticaria, photosensitivity, sunburn, inflammatory diseases, aberrant fibroblast activity and pain.
    Type: Application
    Filed: February 27, 2009
    Publication date: June 7, 2012
    Applicant: MIMETICA PTY LTD
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Publication number: 20110263572
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Application
    Filed: June 6, 2011
    Publication date: October 27, 2011
    Applicant: Mimetica PTY LTD
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Patent number: 8008291
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: August 30, 2011
    Assignee: Mimetica Pty Ltd
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Publication number: 20110059952
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Application
    Filed: February 27, 2009
    Publication date: March 10, 2011
    Applicant: MIMETICA PTY LTD
    Inventors: Mark Arnold Thomas Blaskovic, Peter Joseph Cassidy
  • Publication number: 20110040087
    Abstract: Peptide mimetics of structure X herein which (i) provide a wide range of sidechain functions at all sidechain positions, (ii) can be incorporated in a peptide sequence, (iii) can be readily synthesized and (iv) have a variety of conformations. There is also provided a novel process which can provide valuable intermediates in relation to production of peptide mimetics of structure X which intermediates have a high degree of chemo- and stereo-selectivity. Preferred mimetics include structures I, II, III, IV, V and VI.
    Type: Application
    Filed: August 18, 2010
    Publication date: February 17, 2011
    Applicant: Mimetica Pty Ltd.
    Inventors: Peter Joseph Cassidy, Peter Alan Hunt, Paul Francis Alewood, Tracie Elizabeh Ramsdale
  • Publication number: 20090221557
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Application
    Filed: February 24, 2009
    Publication date: September 3, 2009
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy
  • Publication number: 20090221558
    Abstract: The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases.
    Type: Application
    Filed: February 24, 2009
    Publication date: September 3, 2009
    Inventors: Mark Arnold Thomas Blaskovich, Peter Joseph Cassidy